SUPPLEMENT

Title: SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February – June 2022

 Table S1. Participant characteristics by site

	Kilifi HD	SS		Nairobi	Urban HD	SS
Characteristic	N	n	%	N	n	%
Sex						
Female	852	468	54.9	851	404	47.5
Male	852	384	45.1	851	447	52.5
Age category						
<16 years	852	313	36.7	851	306	36.0
16-24 years	852	86	10.1	851	94	11.0
25-34 years	852	100	11.7	851	100	11.8
35-44 years	852	100	11.7	851	99	11.6
45-54 years	852	102	12.0	851	101	11.9
55-64 years	852	101	11.9	851	100	11.8
>=65 years	852	50	5.9	851	51	6.0
COVID vaccination coverage*						
>=1 doses, all ages	852	94	11.0 (9.0 – 13.3)	851	284	33.4 (30.2 – 36.6)
>=1 doses, >=15 years	559	94	16.8 (13.8 – 20.2)	563	284	50.4 (46.2 – 54.6)
Full vaccination, >=15 years	559	55	9.8 (7.5 – 12.6)	563	211	37.5 (33.5 – 41.6)
History of COVID-like symptoms						
>=1 symptoms in the 2 weeks prior to sample collection	852	177	20.8	851	414	48.6
Symptoms resulting in hospitalization	177	3	1.7	414	6	1.4
Ever confirmed COVID	852	4	0.5	851	18	2.1

^{*95%} confidence intervals indicated in parenthesis

Table S2. Proportion of individuals with anti-S IgG concentrations ≥154 BAU/mL by site, sex, age category and COVID vaccination status, and p-values for stratum-specific tests of equality of anti-S concentration distributions.

KILIFI HDSS	Sample size	n with anti-S IgG ≥154 BAU/mL	Crude proportion with anti-S IgG ≥154 BAU/mL	p-value (equality of distributions test)
Overall	852	534	62.6	Ref
Sex				
Female	468	232	60.4	Ref
Male	384	301	64.3	0.104
Age category				
<16 years	313	169	54.0	Ref
16-24 years	86	58	67.4	0.002
25-34 years	100	67	67.0	<0.001
35-44 years	100	67	67.0	<0.001
45-54 years	102	71	69.6	0.007
55-64 years	101	66	65.3	<0.001
≥65 years	50	35	70.0	0.063
COVID vaccination				
Unvaccinated, ≥15 years	465	293	63.0	Ref
Vaccinated, ≥15 years	94	88	93.6	<0.001
NAIROBI URBAN HDSS	Sample size	n with anti-S IgG ≥154 BAU/mL	Crude proportion with anti-S IgG ≥154 BAU/mL	p-value (equality of distributions test)

Overall	851	731	85.8	<0.001*
Sex				
Female	404	373	83.4	Ref
Male	447	357	88.4	0.013
Age category				
<16 years	306	236	77.1	Ref
16-24 years	94	84	89.4	<0.001
25-34 years	100	84	84.0	<0.001
35-44 years	99	93	93.9	<0.001
45-54 years	101	95	94.1	<0.001
55-64 years	100	93	93.0	<0.001
≥65 years	51	45	88.2	<0.001
COVID vaccination				
Unvaccinated, ≥15 years	279	238	85.3	Ref
Vaccinated, ≥15 years	284	272	95.8	<0.001

^{*}p-value for test of equality of distribution of anti-S IgG concentration cumulative distribution functions at the Kilifi HDSS (ref) vs the Nairobi Urban HDSS, overall.

Table S3. Test-adjusted anti-S IgG seroprevalence (last column) among COVID-unvaccinated participants.

KILIFI HDSS	Sample size	Seropositive	Bayesian population-weighted seroprevalence (95% Crl)	Bayesian population-weighted, test-adjusted seroprevalence (95% Crl)
Overall	758	508	66.7 (63.3-70.0)	72.4 (67.6-77.8)
Sex				
Female	422	293	69.3 (64.7-73.7)	75.2 (69.3-81.4)
Male	336	215	63.8 (58.6-68.7)	69.3 (62.8-76.0)
Age category				
<16 years	312	194	64.4 (59.1-69.0)	69.9 (63.3-76.4)
16-24 years	74	53	68.8 (62.5-76.0)	74.7 (67.2-83.5)
25-34 years	86	59	68.1 (61.6-75.0)	74.0 (66.5-82.0)
35-44 years	88	63	69.2 (63.1-76.1)	75.1 (67.7-83.6)
45-54 years	81	58	69.1 (62.8-76.3)	74.8 (67.4-83.3)
55-64 years	75	51	68.0 (61.1-74.6)	73.8 (65.8-81.9)
≥65 years	42	30	68.9 (61.7-77.0)	74.6 (66.3-84.0)
NAIROBI URBAN HDSS	Sample size	Seropositive	Bayesian population-weighted seroprevalence (95% Crl)	Bayesian population-weighted, test-adjusted seroprevalence (95% Crl)
	Sample size	Seropositive 479	seroprevalence	test-adjusted seroprevalence
URBAN HDSS			seroprevalence (95% Crl)	test-adjusted seroprevalence (95% Crl)
Overall			seroprevalence (95% Crl) 85.3 (82.1-88.2)	test-adjusted seroprevalence (95% Crl) 93.8 (88.2-99.7)
Overall Sex	567	479	seroprevalence (95% Crl)	test-adjusted seroprevalence (95% Crl)
Overall Sex Female	567	479	85.3 (82.1-88.2) 88.5 (84.5-92.0)	test-adjusted seroprevalence (95% Crl) 93.8 (88.2-99.7) 97.4 (91.1-100)
Overall Sex Female Male	567	479	85.3 (82.1-88.2) 88.5 (84.5-92.0)	test-adjusted seroprevalence (95% Crl) 93.8 (88.2-99.7) 97.4 (91.1-100)
Overall Sex Female Male Age category	567 283 284	479 248 231	85.3 (82.1-88.2) 88.5 (84.5-92.0) 82.5 (77.8-86.7)	test-adjusted seroprevalence (95% Crl) 93.8 (88.2-99.7) 97.4 (91.1-100) 90.6 (84.0-99.9)
Overall Sex Female Male Age category <16 years	567 283 284 300	479 248 231 242	85.3 (82.1-88.2) 88.5 (84.5-92.0) 82.5 (77.8-86.7) 81.4 (76.8-85.5)	test-adjusted seroprevalence (95% Crl) 93.8 (88.2-99.7) 97.4 (91.1-100) 90.6 (84.0-99.9) 91.7 (83.7-99.7)
Overall Sex Female Male Age category <16 years 16-24 years	567 283 284 300 60	248 231 242 52	85.3 (82.1-88.2) 88.5 (84.5-92.0) 82.5 (77.8-86.7) 81.4 (76.8-85.5) 86.8 (79.7-92.7)	93.8 (88.2-99.7) 97.4 (91.1-100) 90.6 (84.0-99.9) 91.7 (83.7-99.7) 95.4 (88.2-99.8)
Overall Sex Female Male Age category <16 years 16-24 years 25-34 years	567 283 284 300 60 65	248 231 242 52 55	85.3 (82.1-88.2) 88.5 (84.5-92.0) 82.5 (77.8-86.7) 81.4 (76.8-85.5) 86.8 (79.7-92.7) 85.8 (78.7-91.8)	93.8 (88.2-99.7) 97.4 (91.1-100) 90.6 (84.0-99.9) 91.7 (83.7-99.7) 95.4 (88.2-99.8) 94.0 (86.2-99.8)
Overall Sex Female Male Age category <16 years 16-24 years 25-34 years 35-44 years	567 283 284 300 60 65 48	248 231 242 52 55 45	85.3 (82.1-88.2) 88.5 (84.5-92.0) 82.5 (77.8-86.7) 81.4 (76.8-85.5) 86.8 (79.7-92.7) 85.8 (78.7-91.8) 89.7 (82.5-95.9)	93.8 (88.2-99.7) 97.4 (91.1-100) 90.6 (84.0-99.9) 91.7 (83.7-99.7) 95.4 (88.2-99.8) 94.0 (86.2-99.8) 95.6 (89.2-99.8)

Figure S1. Population density map showing the geographical location of study sites within Kenya. Dots represent 100 population.




Figure S2. Site-specific enrolment periods overlaid on daily number of confirmed cases




Figure S3. Frequency of COVID-like symptoms within the two weeks prior to sample collection overall.





Figure S4. Frequency of COVID-like symptoms within the two weeks prior to sample collection by age category.

A. KILIFI HDSS



B. NAIROBI URBAN HDSS







Figure S5. Reverse cumulative distribution curves of anti-S IgG concentrations within the Kilifi HDSS and Nairobi Urban HDSS by sex (A,D), by age category (B, E) and by COVID vaccination status among individuals aged ≥15 years (C, F). The red vertical line represents an antibody concentration of 154 BAU/mL.



Study data collection form

Study: S-COV-2 HDSS sero- surveys	Location (LOC): □KILIFI- KLF □NAIROBI-NRB	2.1 Participar 2.2 Participar		: (SS- - _ _ LOC S/N	
3. Date of visit (DD/MMM/YYYY):		4.	Staff initials: _ _ _		

5.	5.1 Residency status:a. Presentb. Not at Homec. Await Husband Decision	5.2 Consent: (0= No , 1=Yes, 2=Withdrawn) 5.3 If Consent is NO/Withdrawn: Reason why refused/Withdrawn to participate . a. Parent/Guardian refused consent for the study b. Mother needs the father to give consent and the father is away c. Fear of blood/Swab d. Not interested in the research
	d. Guardian Not Presente. Out Migratedf. Diedg. Not Known	 e. Negative attitude towards KEMRI/ APHRC and KEMRI / APHRC activities f. Prior experience with KEMRI/ APHRC g. Others
6.	6.1 First name:	6.4 Education: (Fill 0=No formal education; 1=Incomplete primary; 2= Complete primary, 3=Incomplete secondary; 4=Complete secondary; 5= Post secondary) 6.5 Religion: (0=None, 1= Muslim 2= Catholic, 3=Protestant; 4= Other Christians, 5= Traditional religion, 6=Hindu, 7=Other(specify))
7.	7.1 Estimated age in years: _	7.2 if <5 years, DOB _ / _ / _ (dd/MMM/yy)
8.	Sex at birth:	(Fill in 0= Female , 1=Male, 2=Other)
9.	Usual place of residence (<u>NOT</u> ancestral home)	
	9.1 County: 9.2 Sub-county: 9.3 Division:	9.4 Location:

10.0	10.1 In the past 3 months, have you experienced any of the following (check all reported symptoms):				
10.0	☐ History of fever : 0= No ; 1=Yes				
	□ Chills : 0= No ; 1=Yes	☐ Shortness of breath/difficulty breathing ☐ Pain (check all that apply)			
	☐ General weakness	□ Diarrhoea: 0= No ; 1=Yes () Muscular () Chest			
	□ Cough: 0= No ; 1=Yes	□ Nausea/vomiting: 0= No ; 1=Yes () Abdominal () Joint			
	□ Sore throat: 0= No ; 1=Yes	□ Headache: 0= No ; 1=Yes			
		=Yes □ Irritability/Confusion : 0= No ; 1=Yes			
	□ Fatigue: 0= No ; 1=Yes-	UNKNOWN (all)			
	□ New loss of taste : 0= No ; 1=Yes	□ Other, specify			
	□ New loss of smell : 0= No; 1=Yes				
	□ Pain (check all that apply): ()Muscular,				
		1) have you experienced in the last 2 weeks:{ } Choose all that apply from Q10			
		11.1 Did any of these symptoms require you to seek medical attention? (Fill in 0= No , 1=Yes, 2= Don't know)			
11.	If you answered yes, Q10,	11.2 Did any of these symptoms cause you to miss work? (Fill in 0= No , 1=Yes, 2= Don't know)			
		11.3 Did any of these symptoms require you to be hospitalised? (Fill in 0= No , 1=Yes, 2= Don't know)			
		12.1 Have you had a COVID-19 vaccine? (Fill in 0= No , 1=Yes, 2= Don't know)			
		COVID vaccine type? (1 – AstraZeneca, 2 – Pfizer, 3- Johnson & Johnson, 4 -Moderna, 5 - SputnikV, 6-Sinopharm; 7- Others(Type), 8=Don't Know)			
12.	COVID-19 vaccination status	12.2 How many doses? (1 dose=1, 2 doses =2, 3 doses-3) a) Dose 1 type: date _d_ d_ / _m_ _m_ m_ / _y_ y_ b) Dose 2 type: date _d_ d_ / _m_ m_ _m_ / _y_ y_ c) Dose 3 type: date _d_ d_ / _m_ m_ m_ / _y_ y_ 12.3 Vaccination confirmed by: 1=Vaccination Card; 2= SMS; 3= Verbal report; 4=Other(specify)			
13.	Check for BCG scar (first look at the left, then the right shoulder)	13.1 Does the participant have a BCG scar? (Fill in 0= No , 1=Yes, 2= Don't know)			
14.	For children < 5 years, vaccination information from health card	14.1 Do you have vaccination records for (child's Name)? (Fill in 0= No , 1=Yes) If you answered YES, in 20.1, Capture Vaccination history from the records provided (Fill in 0= No , 1=Yes, 2= Don't know) 14.2 BCG if yes, fill in date _d _ _d _ / _m _ _m _ _m _ / _y _ _y _ 14.3 Penta 1 if yes, fill in date _d _ _d _ / _m _ _m _ _m _ / _y _ _y _ 14.4 Penta 2 if yes, fill in date _d _ _d _ / _m _ _m _ _m _ / _y _ _y _ 14.5 Penta 3 if yes, fill in date _d _ _d _ / _m _ _m _ _m _ / _y _ _y _ 14.6 PCV 1 if yes, fill in date _d _ _d _ / _m _ _m _ _m _ / _y _ _y _ 14.7 PCV 2 if yes, fill in date _d _ _d _ / _m _ _m _ _m _ / _y _ _y _ 14.9 MCV1 if yes, fill in date _d _ _d _ / _m _ _m _ _m _ / _y _ _y _ 14.10 MCV2 if yes, fill in date _d _ _d _ / _m _ _m _ _m _ / _y _ _y _ 1f you answered NO, in 20.1, 14.11 Reason why vaccination card is not available. (Choose from the List of probable reasons why no records provided) 1. Mother/guardian who keeps the card is not available 2. Claims to have had a card but misplaced it 3. Was not issued with the card at the health facility but received vaccinations 4. Has never gotten a card and never received vaccinations 5. Card Destroyed/burnt			
		6. Card left at another place other than the current residence			
15	Have you ever tested for COVID?)? (Fill in 0= No , 1=Yes)	If Positive , Date of last positive test d_ d_ _m_ _m_ / _y_ _y_			

16.	Time of sample collection (hh:mm; 24hr		or N/A sample not taken
	clock)	·	or 1 N/A sample not taken

Form completed by: ______(Signature) |__|_|/|_|_|_|/|_2_|_0_|__| |(Date (dd/MMM/yyyy))